Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial - PubMed - Ausgewählte Studien - Psoriasis-News

Zum Inhalt springen

Psoriasis-News

Bereits registriert? Anmelden
Anmelden

Angemeldet bleiben Nicht empfohlen auf gemeinsam genutzten Computern

Passwort vergessen?
Jetzt registrieren

Ausgewählte Studien

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial - PubMed
Teilen
https://www.psoriasis-news.de/studien/germany/sustained-response-to-guselkumab-regardless-of-baseline-characteristics-in-patients-with-active-psoriatic-arthritis-and-inadequate-response-to-tnf-inhibitors-results-from-the-phase-3b-cosmos-clinical-trial-pubmed-r715/

Folgen 0
Objectives: To prospectively evaluate the effect of guselkumab through 48 weeks across various clinical outcomes in subgroups of patients with …
Den ganzen Artikel lesen
Von Automat

14. Dezember
Teilen
https://www.psoriasis-news.de/studien/germany/sustained-response-to-guselkumab-regardless-of-baseline-characteristics-in-patients-with-active-psoriatic-arthritis-and-inadequate-response-to-tnf-inhibitors-results-from-the-phase-3b-cosmos-clinical-trial-pubmed-r715/
Folgen 0
Zurück zu Datensätze

×

×

Neu erstellen...